top of page
Firefly_3D render of multiple transparent Y-shaped antibody molecules floating in a soft g

TZ-Ab102

SdAb Discovery to Cancer Treatment

TZ_Ab102 has been developed for precise cancer treatment by targeting
peptide–MHC complexes. In this effort, single-domain antibody (sdAb) emerged as a
promising binder with the required specificity and stability.

Building on this insight, an sdAb was engineered to recognize the WT1-derived
peptide–HLA complex with high affinity, and its potential was demonstrated in a
CAR-T format.

These results highlight the promise of sdAbs as a new class of therapeutics for

pMHC-targeted cancer immunotherapy.

Firefly_A premium 3D render of a complex protein structure, composed of intertwined alpha-

Mode of Action & In vitro Efficacy

Crystal Structure

Cytotoxcity Test (CAR-T)

figure_transparent_clean.png

sdAb

WT1 derived peptide

MHC I
(HLA-A*02:01/β2M)

image.png

RMF peptide

p53(R175H) peptide

IL-2 (pg/ml)

1000

500

0

-12

-11

-10

-4

-5

-6

-7

-8

-9

Cell: T2

Log([peptide], M)

image.png

RMF peptide

p53(R175H) peptide

IL-2 (pg/ml)

1000

500

0

Cell: 721.221 (HLA-A*02:01+/TAP-)

Log([peptide], M)

-12

-11

-10

-4

-5

-6

-7

-8

-9

Progress

Design

Lead

IND Enabling

Remarks

Asset

Hit

Preclinical Study

TZ-Ab102

Awarded a national
research grant

Publication

Computational design of a single-domain antibody that specifically recognizes WT1 peptide-loaded class I MHC

​​

Tae-Sung Oh, Sang Pil Ahn, Seonghyuk Suh, JooYeon Lee, Yeong-Nam Bae, Hyejin Lee, Yong-Sung Kim, 

Bo-Seong Jeong, Byung-Ha Oh

bottom of page